Oral Nadolol for the Treatment of Adults With Mild Asthma

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Invion, Inc.
• Collaborators: Baylor College of Medicine; Sandler Program for Asthma Research; University of Houston
• Treatments: Nadolol

Criteria

Inclusion Criteria:

• Pre-bronchodilator FEV1 80% or greater than the predicted value.

• PC20 FEV1 ≤4 mg/ml on methacholine challenge test.

• Blood Pressure ≥ 100/65mm Hg.

• Pulse rate ≥ 60 beats/min.

• No significant health issues.

• Non-smoker or X-smoker < 10 pack/year.

Exclusion Criteria:

• History of upper/lower respiratory tract infection or asthma exacerbation within 6 weeks of first baseline visit.

• Currently diagnosed with chronic obstructive pulmonary disease (COPD).

• Used any oral or inhaled corticosteroids within 4 weeks of the first baseline visit.